Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 02, 2023

Rates and Predictors of Early Discontinuation of Metformin, Placebo, and Endocrine Therapy Among Patients With Hormone Receptor–Positive Early-Stage Breast Cancer

Breast Cancer Research and Treatment

 

Additional Info

Breast Cancer Research and Treatment
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)
Breast Cancer Res Treat 2023 Jul 01;200(1)93-102, DL Hershman, BE Chen, C Sathe, WR Parulekar, J Lemieux, JA Ligibel, KA Gelmon, TJ Whelan, PJ Goodwin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading